Table 2.

Clinicopathological features and the changes of tumor IDO1 expression and CD8+TILs density after neoadjuvant therapy.

		IDO1-rise	IDO1-decline	p	L-ΔCD8	H-ΔCD8	P
Total	85 (100%)	39 (45.9%)	46 (54.1%)		50 (58.8%)	35 (41.2%)
Age				0.075			0.919
<70 years	70 (82.4%)	29 (74.4%)	41 (89.1%)		41 (82.0%)	29 (82.9%)
≥70 years	15 (17.6%)	10 (25.6%)	5 (10.9%)		9 (18.0%)	6 (17.1%)
Sex				0.973			0.536
Male	59 (69.4%)	27 (69.2%)	32 (69.6%)		36 (72.0%)	23 (65.7%)
Female	26 (30.6%)	12 (30.8%)	14 (30.4%)		14 (28.0%)	12 (34.3%)
Tobacco use				0.554			0.407
Yes	32 (37.6%)	16 (41.0%)	16 (34.8%)		17 (34.0%)	15 (42.9%)
No	53 (62.4%)	23 (59.0%)	30 (65.2%)		33 (66.0%)	20 (57.1%)
Alcohol use				0.473			0.499
Yes	40 (47.1%)	20 (51.3%)	20 (43.5%)		22 (44.0%)	18 (51.4%)
No	45 (52.9%)	19 (48.7%)	26 (56.5%)		28 (56.0%)	17 (48.6%)
Clinical stage				0.098			0.019
II	32 (37.6%)	11 (28.2%)	21 (45.7%)		24 (48.0%)	8 (22.9%)
III/IV	53 (62.4%)	28 (71.8%)	25 (54.3%)		26 (52.0%)	27 (77.1%)
TRG				0.002			0.636
I/II	63 (74.1%)	35 (89.7%)	28 (60.9%)		38 (76.0%)	25 (71.4%)
III/IV	22 (25.9%)	4 (10.3%)	18 (39.1%)		12 (24.0%)	10 (28.6%)
Neoadjuvant therapy				0.009			0.028
NCT	68 (80.0%)	36 (92.3%)	32 (69.6%)		44 (88.0%)	24 (68.6%)
NCRT	17 (20.0%)	3 (7.7%)	14 (30.4%)		6 (12.0%)	11 (31.4%)
Pathological staging				0.031			0.139
I/II	54 (63.5%)	20 (51.3%)	34 (73.9%)		35 (70.0%)	19 (54.3%)
III/IV	31 (36.5%)	19 (48.7%)	12 (36.5%)		15 (30.0%)	16 (45.7%)
pN staging				0.029			0.108
N0	50 (58.8%)	18 (46.2%)	32 (69.6%)		33 (66.0%)	17 (48.6%)
N+	35 (41.2%)	21 (53.8%)	14 (30.4%)		17 (34.0%)	18 (51.4%)
Nerve invasion				0.015			0.407
Negative	72 (84.7%)	29 (74.4%)	43 (93.5%)		41 (82.0%)	31 (88.6%)
Positive	13 (15.3%)	10 (25.6%)	3 (6.5)		9 (18.0%)	4 (11.4%)
Vascular cancer embolus				0.019			0.103
Negative	70 (82.4%)	28 (71.8%)	42 (91.3%)		44 (88.0%)	26 (74.3%)
Positive	15 (17.6%)	11 (28.2%)	4 (8.7%)		6 (12.0%)	9 (25.7)